BDX stock: buy or sell?
October 18th, 2019
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide.
Should I buy BDX stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Becton, Dickinson and stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Becton, Dickinson and stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 14 ratings published for BDX stock in the last month. The general sentiment of these ratings is bullish for BDX stock, with 7 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-9-6||Wells Fargo & Co||n/a||Outperform|
|2019-8-6||Piper Jaffray Companies||n/a||Overweight|
|2019-7-16||Morgan Stanley||n/a||Equal Weight|
|2019-5-13||Wells Fargo & Co||n/a||Outperform|
|2019-5-10||Morgan Stanley||n/a||Equal Weight|
|2019-4-15||Barclays||Equal Weight||Equal Weight|
|2019-2-5||Piper Jaffray Companies||n/a||Overweight|
|2019-1-2||Morgan Stanley||Equal Weight||Equal Weight|
BDX stock analysis
Becton, Dickinson and raised a slightly good 0.70% and closed at $258.59.
On September 6th, BDX hit new all time highs, pushing higher previous ATH of $262.57 recorded . New ATHs are usual entry points for many trading setups as there aren't higher resistences. Shares of Becton, Dickinson and ended on Oct 18th at $258.59 and raised a slightly good 0.70%. On August BDX price bounced up over the SMA of 200 days demonstrating to be a significant support for this stock. On June, SMA100d and SMA200d crossed up triggering a rise of 8.71%.
Shares of Becton, Dickinson and inched a fine 2.27% this week.
Not so far away is the last all-time high Becton, Dickinson and marked early September. From a weekly outlook, BDX marked an uptrend of rising tops and rising bottoms. Since its last top early September at $264.74, price slid and bounced up back from $244.09. Breaking down under $244.09 would cancel the current uptrend and it might test lower supports. Note that $264.74 might act as a resistance line. Since mid June when BDX stock price broke up the SMA40w line, it gained $25.13 (10.76%). Late May, SMA20w and SMA40w crossed up triggering a rise of 13.94%.
BDX stock price history
BDX stock historical price chart
BDX stock reached all-time highs on Sep 6th with a price of $264.74.
BDX stock price target is $265.30Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' BDX stock price predictions in the hope that they will be met as they may be wrong and not met. We have 14 price forecasts for BDX stock posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-9-6||Wells Fargo & Co||Raises Target||$270.00||$290.00||7.4%|
|2019-8-6||Piper Jaffray Companies||Reiterates||$267.00||$266.00||-0.4%|
|2019-7-16||Morgan Stanley||Raises Target||$250.00||$261.00||4.4%|
|2019-6-28||Raymond James||Raises Target||$265.00||$288.00||8.7%|
|2019-5-13||Wells Fargo & Co||Reiterates||$280.00||$265.00||-5.4%|
|2019-5-10||UBS Group||Lowers Target||$265.00||$250.00||-5.7%|
|2019-5-10||Morgan Stanley||Lowers Target||$255.00||$250.00||-2%|
|2019-3-19||Raymond James||Lowers Target||$290.00||$280.00||-3.4%|
|2019-2-5||Piper Jaffray Companies||Raises Target||n/a||$274.00||-|
|2019-1-2||Morgan Stanley||Lowers Target||$265.00||$240.00||-9.4%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on February, Becton, Dickinson and . Unfortunately, reported EPS is not yet available in our database.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a super good gain of 32.17% to $15,983.00 M dollars. When comparing 2018 vs 2017, instead, profit margin (that is, the net income divided by revenues) eased a -7.15% to 1.95%. To have an updated view of the financial situation of Becton, Dickinson and, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual Becton, Dickinson and TTM sales up to December 2018 were $17,062.00 and earnings were $1,046.00 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Becton, Dickinson and business evolution since September 2018: Annual sales up to December, compared to lastest yearly report, rose an excellent 6.75%. In line, profit margin (net income/sales) appreciated at 1.95%.
|2013||$8,050 M||-||$929 M11.5%||-|
|2014||$8,446 M||4.92%||$1,185 M14.0%||27.56%|
|2015||$10,282 M||21.74%||$695 M6.8%||-41.35%|
|2016||$12,483 M||21.41%||$976 M7.8%||40.43%|
|2017||$12,093 M||-3.12%||$1,100 M9.1%||12.70%|
|2018||$15,983 M||32.17%||$311 M1.9%||-71.73%|
|TTM||$17,062 M||6.75%||$1,046 M6.1%||236.33%|
Quarterly financial resultsBecton, Dickinson and posted $4,160.00 M in sales for 2018-Q4, a -5.50% decline compared to previous quarter. Reported quarter earnings marked $599.00 M with a profit margin of 14.40%. Profit margin rocketed a 17.47% compared to previous quarter when profit margin was -3.07%. When comparing revenues to same quarter last year, Becton, Dickinson and sales marked an extraordinary increase and boosted a 35.06%.
|2017-Q1||$2,970 M||-||$344 M11.6%||-|
|2017-Q2||$3,040 M||2.36%||$-132 M-4.3%||-138.37%|
|2017-Q3||$3,166 M||4.14%||$327 M10.3%||-347.73%|
|2017-Q4||$3,080 M||-2.72%||$-136 M-4.4%||-141.59%|
|2018-Q1||$4,222 M||37.08%||$-12 M-0.3%||-91.18%|
|2018-Q2||$4,278 M||1.33%||$594 M13.9%||-5,050.00%|
|2018-Q3||$4,402 M||2.90%||$-135 M-3.1%||-122.73%|
|2018-Q4||$4,160 M||-5.50%||$599 M14.4%||-543.70%|
Becton, Dickinson and ownershipWhen you are planning to buy a stock, it's worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Becton, Dickinson and, 0.26% of all outstanding shares are owned by its staff.
Bearish positions for BDX stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
|Market cap||$69.8 B||$44.9 B||$8.5 B||$108.4 M||$13.3 B|
|Total shares||270.0 M||510.6 M||24.7 M||38.1 M||267.3 M|
|Float shares||269.1 M||509.6 M||21.3 M||28.6 M||266.1 M|
|- Institutional holdings (%)||87.5%||88.2%||78.0%||74.1%||99.7%|
|- Insider holdings (%)||0.3%||0.1%||14.6%||12.9%||0.3%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, October 18th, 2019|
|Day range||$255.74 - $259.12|
|Average true range||$4.45|
|50d mov avg||$252.78|
|100d mov avg||$249.44|
|200d mov avg||$244.15|
Becton, Dickinson and performanceTo better understand Becton, Dickinson and performance you must becnhmark its gains with other related stocks in same sector or industry. In the following table, we compare Becton, Dickinson and performance to Baxter International, Bio-Rad Laboratories, Harvard Bioscience, Hologic, Intuitive Surgical, ResMed, Teleflex, Thermo Fisher Scientific, Varian Medical Systems and DENTSPLY SIRONA:
|TMOThermo Fisher Sci...||-2.84%||8.47%||24.23%|
|VARVarian Medical Sy...||-13.69%||-12.36%||10.01%|